Results 31 to 40 of about 13,819 (183)

Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience

open access: yesHaematologica, 2012
Background Posaconazole is effective as primary antifungal prophylaxis of invasive fungal diseases in patients with acute myeloid leukemia.Design and Methods The impact of primary antifungal prophylaxis administered during front-line chemotherapy for ...
Corrado Girmenia   +14 more
doaj   +1 more source

Rhabdomyolysis Following Initiation of Posaconazole Use for Antifungal Prophylaxis in a Patient With Relapsed Acute Myeloid Leukemia

open access: yesJournal of Investigative Medicine High Impact Case Reports, 2017
Posaconazole is a commonly used medication for antifungal prophylaxis in patients with high-risk acute leukemia, such as acute myeloid leukemia. Despite clinical data that show that posaconazole is superior to other antifungal prophylaxis medications ...
Mayur D. Mody MD   +3 more
doaj   +1 more source

Comparative clinical and economic analysis of pozaconazol (Noxafil) for invasive mycoses (IM) prevention in patients with severe neutropenia during treatment of acute myeloid leukemia or myelodysplastic syndrome

open access: yesОнкогематология, 2019
Objective: a comparative clinical and economic analysis of posaconazole (Noxafil) for invasive mycoses (IM) prevention in patients with severe neutropenia during treatment of acute myeloid leukemia or myelodysplastic syndrome in Russia.
I. S. Krysanov   +3 more
doaj   +1 more source

The tablet formulation of posaconazole: clinical pharmacology and the use in patients with hematologic malignancies [PDF]

open access: yesКлиническая микробиология и антимикробная химиотерапия, 2020
Posaconazole is a broad-spectrum triazole antifungal agent with potent activity against various fungi, including yeast and molds, including Mucorales, what makes a key difference with itraconazole and voriconazole.
Veselov A.V.
doaj   +1 more source

Posaconazole and fluconazole prophylaxis during induction therapy for pediatric acute lymphoblastic leukemia

open access: yesJournal of Microbiology, Immunology and Infection, 2021
Purpose: To assess and compare the efficacy and safety of posaconazole with fluconazole for the prevention of invasive fungal infections in children who were undergoing induction therapy for acute lymphoblastic leukemia (ALL).
Tian Zhang   +6 more
doaj  

Posaconazole-Induced Adrenal Insufficiency in a Case of Chronic Myelomonocytic Leukemia

open access: yesCase Reports in Endocrinology, 2018
Introduction. Posaconazole is an azole used in treatment and prophylaxis of a broad spectrum of fungal infections. Antifungals such as ketoconazole have been shown to cause primary adrenal insufficiency (AI) as a result of direct inhibition on the ...
Ann Miller   +3 more
doaj   +1 more source

Mineralocorticoid hypertension and hypokalaemia induced by posaconazole

open access: yesEcho Research and Practice, 2018
We describe severe hypokalaemia and hypertension due to a mineralocorticoid effect in a patient with myelodysplastic syndrome taking posaconazole as antifungal prophylaxis.
Charlotte Boughton   +4 more
doaj   +1 more source

Posaconazole: A Review of Drug Interactions with HIV Antiretroviral Agents

open access: yesPharmacy, 2014
The purpose of this review is to examine the literature for reports of clinically significant interactions noted amongst HIV antiretroviral medications when coadministered with posaconazole.
Mara Poulakos, Amy Henneman, Simon Leung
doaj   +1 more source

Factors associated with subtherapeutic levels of oral posaconazole tablet: a detailed analysis from a tertiary care center in India

open access: yesInternational Journal of Infectious Diseases, 2022
Objectives: Posaconazole is a broad-spectrum triazole antifungal, with activity against various clinically important fungi. The delayed release (DR) tablet of posaconazole has been shown to have a superior pharmacokinetic profile in comparison with the ...
Parikshit S. Prayag   +8 more
doaj  

Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation

open access: yesBMC Infectious Diseases, 2012
Background Pediatric patients undergoing hematopoietic stem cell transplantation (HSCT) are at high risk of acquiring fungal infections. Antifungal prophylaxis shortly after transplantation is therefore indicated, but data for pediatric patients under 12
Döring Michaela   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy